Work

First-in-human (FIH) phase 1 study of CUSP06, a cadherin-6 (CDH6)-directed antibody-drug conjugate (ADC), in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.3042

Authors: Manish R. Patel, Gerald Steven Falchook, Elizabeth Katherine Lee, Alexander I. Spira, Vivek Subbiah, Debra L. Richardson, Patricia LoRusso, Roisin Eilish O'Cearbhaill, Nicole Covino, Wei Lu, Priya Marreddy, Daphne L. Farrington, Hagop Youssoufian, Eric Daniel Slosberg, Funda Meric-Bernstam

Institutions: HealthONE, Dana-Farber Cancer Institute, Virginia Cancer Specialists, Sarah Cannon, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Yale Cancer Center, Yale University, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410812372

Cites:

Cited by: 4

Related to: 10